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ABSTRACT 
 
Some recombinant adeno-associated viruses (rAAVs) can cross the neonatal blood-brain 
barrier (BBB) and efficiently transduce cells of the central nervous system (CNS). However, in 
the adult CNS, transduction levels by systemically delivered rAAVs are significantly reduced, 
limiting their potential for CNS gene therapy. Here, we characterized 12 different rAAVEGFPs in 
the adult mouse CNS following intravenous delivery. We show that the capability of crossing the 
adult BBB and achieving widespread CNS transduction is a common character of AAV 
serotypes tested. Of note, rAAVrh.8 is the leading vector for robust global transduction of glial 
and neuronal cell types in regions of clinical importance such as cortex, caudate-putamen, 
hippocampus, corpus callosum and substantia nigra. It also displays reduced peripheral tissue 
tropism compared to other leading vectors. Additionally, we evaluated rAAVrh.10 with and 
without microRNA (miRNA)-regulated expressional detargeting from peripheral tissues for 
systemic gene delivery to the CNS in marmosets. Our results indicate that rAAVrh.8, along with 
rh.10 and 9, hold the best promise for developing novel therapeutic strategies to treat 
neurological diseases in the adult patient population. Additionally, systemically delivered 
rAAVrh.10 can transduce the CNS efficiently and its transgene expression can be limited in the 
periphery by endogenous miRNAs in adult marmosets. 
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INTRODUCTION 
 
The increasing prevalence of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and 
Amyotrophic Lateral Sclerosis (ALS) is a growing public health concern for the US population 
and devastating for patients and their families. By 2050, an estimation of 16 million Americans 
will suffer from Alzheimer’s disease with total costs of $1.1 trillion (in today’s dollars) [1, 2]. 
Conventional approaches to treat neurodegenerative diseases are limited to managing 
symptoms and curbing disease progression [3]. In spite of some exciting progress in the broad 
biomedical research field, overall efforts in developing conventional therapeutics to ameliorate 
or even cure neurodegenerative diseases have had limited clinical success. CNS-directed gene 
therapy is a promising approach for treating neurodegenerative diseases and offers some 
advantages over conventional remedies, which could ultimately lead to tissue specific, long-term 
delivery of therapeutic agents and curative measures [4-9]. 
 
A significant barrier of CNS gene-delivery is the blood brain barrier (BBB), which prevents large 
or hydrophilic molecules such as dopamine, chemotherapeutics and viruses from passively 
entering the brain [10, 11]. On the other hand, rAAVs hold promise for efficient, stable, and safe 
gene delivery to a wide range of tissues including the CNS [4, 8, 12-15], but methods of delivery 
for rAAV-mediated gene transfer remain an intricate and demanding aspect of vector-based 
CNS gene therapy. Direct stereotactic injections of rAAVs are ideal for diseases with local CNS 
pathology, but cannot transduce the CNS broadly [16]. This can be accomplished by systemic 
rAAV delivery that utilizes the ramified capillary network of the CNS to ameliorate widespread 
pathologies in the CNS. Although systemic delivery of the first generation of rAAV2 to the CNS 
has proven to be difficult, it can be marginally improved by transient pharmacological 
modulation of the BBB, producing a limited CNS transduction [17]. 
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Recent discoveries of new clades of primate AAVs have substantially expanded potential 
applications of rAAVs in preclinical and clinical gene therapy [14, 18-21]. Importantly, one of 
these novel primate serotypes, rAAV9, can achieve robust transduction of neuronal and glial cell 
types in the CNS of murine neonates following intravenous injections and has shown 
encouraging results in treating a number of CNS diseases that require early-life intervention [4, 
6, 8, 15, 22]. Studies in adult animals, however, demonstrated significantly restricted entry of 
viral particles into the CNS and declined transduction efficiency due to the advanced BBB 
development [15, 23]. In searching for means to overcome this limitation, a subsequent study by 
our group has identified several additional rAAVs that are as or more effective as rAAV9 in 
transducing the neonatal CNS [22], which motivated our selection of rAAVs for adult 
transduction in the current study. 
 
A serious challenge to rAAV9-mediated systemic gene delivery to the CNS is the lack of CNS-
restricted tropism and therapeutic functionality, which results in simultaneous robust 
transduction of peripheral tissues such as liver, heart, lung, muscle and pancreas [23-25]. 
Although endogenous miRNA-regulated rAAV9 is capable of detargeting transgene expression 
from peripheral tissues towards CNS-restricted transgene expression in mice [26], an expanded 
repertory of rAAV vectors with discriminating tropism for the CNS and a reduced affinity for 
peripheral tissues will be desirable to limit potential peripheral toxicity, allow for greater 
therapeutic control and flexibility as well as bypassing possible pre-existing immunity to rAAV9 
in patient populations [27-29]. 
 
In order to identify highly CNS tropic rAAV(s) with naturally reduced peripheral tissue tropism for 
systemic gene delivery to the CNS, we compared the CNS transduction efficiencies of 12 
different rAAVs (rAAV 1, 2, 5, 6, 6.2, 7, 8, 9, rh.8, rh.10, rh.39 and rh.43) in 10 weeks old adult 
mice following systemic delivery and performed a proof-of-concept study of systemically 
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delivered rAAVrh.10 with and without miRNA-regulated transgene expression in nonhuman 
primates. We report that rAAVrh.8 is a novel and superior vector, displaying strong tropism 
towards clinical relevant regions of the CNS with reduced dissemination to peripheral tissues in 
mice. We also demonstrate in a proof-of-concept study for the first time the successful CNS 
gene transfer by systemically delivered rAAVrh.10 and miRNA–regulated transgene expression 
in nonhuman primates (NHPs). 
 
RESULTS 
Seven rAAV vectors can achieve efficient global transduction of the adult mouse CNS.  
To determine the transduction efficiency of each serotype after I.V. injection, we detected and 
quantified the EGFP signal from the coronal sections of brains and transversal sections of 
cervical, thoracic and lumbar spinal cords (Figs. 1-3). Based on the density of the transduced 
cells (see Materials and Methods), we grouped 12 rAAVs into four groups (Figs. 1 and 2; Suppl. 
Table 1). Group 1 is consisted of three vectors, rAAVrh.8, rAAVrh.10 and rAAV9. This group 
ranked consistently as the top three in the transduction levels in both brain and spinal cord. The 
only exception is the spinal cord neurons, where the top seven vectors showed similar levels of 
transduction (Fig. 3G; Suppl. Fig. 1). Group 2 is consisted of four vectors, rAAV7, rAAV8, 
rAARrh.39 and rAAVrh.43. This group ranked lower than the group 1 but their overall 
transduction levels were still excellent. In some cases (e.g. total spinal cord and spinal cord 
neurons), the differences between this group and group 1 were small and insignificant (Figs. 1, 
2 and 3C, G, Suppl. Tab. 1). All the group 1 and group 2 vectors transduced spinal cord motor 
neurons robustly (Suppl. Fig. 1). Group 3 is consisted of three vectors, rAAV1, rAAV6 and 
rAAV6.2. The transduction levels by this group were lower than groups 1 and 2. In most 
instances, rAAV6.2 ranked the highest and the AAV1 the lowest within this group (Figs. 1-3, 
Suppl. Fig. 1). This group had high transduction of blood vessels (data not shown). Group 4 is 
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consisted of two vectors, rAAV2 and rAAV5. This group had the lowest transduction levels (Figs. 
1-3). rAAV5 transduced few or no cells as well as blood vessels in the CNS. rAAV2 transduced 
small populations of neurons in the dentate gyrus and the hypothalamus, and scattered 
astrocytes and neurons in the cortex and some ependymal cells (Data not shown). Based on 
these assessments, we focused our detailed analysis on the group 1 vectors and some 
representatives of group 2 and group 3 vectors. 
rAAVrh.8 is the most efficient vector in transducing the adult CNS. The group 1 vectors 
transduced cells in wide areas of the CNS, including cortex, striatum, hippocampus, thalamus, 
hypothalamus, amygdale, corpus callosum (Figs. 1 and 4; Suppl. Figs. 2 and 3), the choroid 
plexus (Suppl. Fig. 4) and all three spinal cord regions (i.e. cervical, thoracic and lumbar) (Fig. 
2; Suppl. Fig. 1). Overall rAAVrh.8 appeared to transduce most robustly relative to other 
vectors. rAAVrh.8 consistently ranked first in different regions and in different cell types (Fig. 
3A-I) by a semi-quantitative scoring system (see Materials and Methods) [16]. The only 
exception was in the spinal neurons, where the top 7 serotypes had essentially the same 
transduction efficiency (Fig. 3G). 
The group 1, 2 and 3 vectors transduce multiple cell types and various neuronal 
populations in the CNS. To identify the cell types that the vectors transduce, we first carried 
out morphological analysis on the CNS tissue sections stained for GFP. By high magnification 
microscopy we observed extensive transduction of neurons, astrocytes and oligodendrocytes in 
various areas of the CNS (Figs. 3 and 4; Suppl. Figs. 1-3). For example, the group 1 vectors 
transduced granular cells in dentate gyrus (Fig. 4B, Suppl. Figs. 2 and 3B), pyramidal neurons 
in CA2 (Fig. 4D, Suppl. Figs. 2 and 3D), medial spiny neurons and astrocytes in striatum (Fig. 
4E; Suppl. Figs. 2 and 3E), Purkinje neurons in cerebellum (Fig. 4 Cerebellum; Suppl. Figs. 2 
and 3J), neurons and astrocytes in thalamus (Fig. 4H; Suppl. Fig. 2 and 3H), hypothalamus 
(Fig. 4G; Suppl. Fig. 3G), amygdala (Fig. 4I; Suppl. Fig. 3I), layer 3-6 of the cortex (Fig. 4 A, F; 
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Suppl. Figs. 2 and 3 A, F), substantia nigra (Fig. 4 SN; Suppl. Fig. 3K), ventral tegmental area 
(not shown) and lateral septum (Fig. 4 LSN; Suppl. Fig. 3L). Additionally, they also transduced 
oligodendrocytes in corpus callosum (Fig. 4C; Suppl. Figs. 2 and 3C). A similar cellular 
transduction pattern was also observed for group 2 and 3 vectors, albeit that the density of 
transduced cells was lower than group 1 vectors (Figs. 1 and 2; Suppl. Fig. 2). To verify the 
transduced cell types, we performed double fluorescence staining on the rAAVrh.8-treated CNS 
tissues. Using markers for specific cell types, including NeuN for neurons, GFAP for astrocytes, 
APC for oligodendrocytes, Iba1 for microglia and CD31 for blood vessels, we verified that EGFP 
was expressed in neurons, astrocytes, oligodendrocytes and blood vessels, but not in microglia 
(Fig. 5). We also verified EGFP expression in several specific neuronal subpopulations, 
including Purkinje cells (calbindin), motor neurons (ChAT), medial spiny neurons (Darpp-32) 
and dopaminergic neurons (tyrosine hydroxylase) (Suppl. Fig. 5). 
rAAVrh.8 injections result in less peripheral tissue dissemination compared to rAAV9 
and rAAVrh.10. In addition to strong and widespread transduction in the CNS, we consider low 
peripheral tropism to be an important property of an ideal viral vector for systemically delivered 
and CNS-targeted gene therapy. To characterize biodistribution profiles of I.V. delivered rAAV in 
various tissues of the injected mice, qPCR quantification of rAAV genomes was carried out for 
the group 1 vectors in brain, spinal cord, lung, kidney, pancreas, skeletal muscle, heart and liver 
tissues (Fig. 6A). The copy numbers of persistent rAAVrh.8 genomes were similar to those of 
rAAV9 and rAAVrh.10 in the brain but significantly lower than rAAV9 and rAAVrh.10 in the liver. 
To assess the degree of transduction in the brain relative to the peripheral tissues, we 
calculated the ratios between the genome copies in the brain and those in the periphery. We did 
not detect a significant difference between the vectors in the group 1 probably due to a high 
degree of variation among the injected animals (Fig. 6B). Nevertheless, we observed a trend 
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
towards relatively high CNS transduction over the periphery for rAAVrh.8 compared with 
rAAVrh.10 and rAAV9.  
Systemically delivered rAAVrh.10 transduces the motor neurons of adult marmosets. To 
determine CNS transduction efficiency in NHPs by I.V. injection, we conducted a proof-of-
concept experiment. We intravenously dosed two adult marmosets, one with rAAVrh.10EGFP 
and the other with rAAVrh.10EGFP-miR-1BS-miR-122BS3 (rAAVrh.10EGFP-miRBS). The latter 
vector expresses EGFP and carries three repeated copies of miRNA binding sites in its 3’-UTR 
for miR-1 that is abundant in heart and muscle and miR-122 that is abundant in liver [30]. 
Consequently, these endogenously expressed miRNAs can bind to the transgene/EGFP mRNA 
in heart, skeletal muscle and liver and thus repress the transgene expression. A third marmoset 
was injected with rAAVrh.10EGFP intrathecally for comparison. The animals were euthanized 2 
weeks after injection and the EGFP expression in both CNS and peripheral tissues were 
analyzed. The results of CNS transduction for the intrathecally injected monkey were published 
elsewhere [27]. The data for CNS transduction in two I.V. injected animals and peripheral tissue 
transductions in all 3 monkeys are presented below.  
I.V. injection of rAAVrh.10EGFP to the one adult marmoset generated striking EGFP 
transduction in motor neurons throughout the entire length of the spinal cord (Fig. 7A-F) and 
oculomotor nucleus resided in the ventral midbrain (Fig.7G-I). Additionally, the axon fibers in the 
posterior horn and cuneate fasciculus at the cervical and thoracic levels robustly expressed 
EGFP (Suppl. Fig. 6A, C), indicating that the neurons in the dorsal root ganglia (DRG) were 
well transduced at these regions. The axon fibers in the posterior horn and cuneate fascicules at 
the lumbar level and the neurons and astrocytes in the intermediate zone of the spinal cord also 
expressed EGFP, although the expression in these regions was not as strong as the ventral 
horns at all levels and the dorsal horns at the cervical and thoracic levels (Fig. 7A-F; Suppl. Fig. 
6). The brain was overall sparsely transduced but focal regions with strong EGFP expression 
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could be observed, e.g. spinal trigeminal nucleus and tract (Suppl. Figs. 7 A, G and 9). Other 
areas with noticeable transduction were vestibular nucleus, hypoglossal nucleus, inferior olive 
nucleus, lateral reticular nucleus, red nucleus and substantial nigra (Suppl. Figs. 7 and 8). The 
rest brain areas including cerebral cortex, cerebellum and hippocampus were sparsely 
transduced (Suppl. Fig. 9).  
I.V. injection of rAAVrh.10EGFP-miRBS to the second adult marmoset resulted in generally 
sparse EGFP transduction throughout the CNS except for some focal regions of hypoglossal 
nucleus, nucleus of vagus, gigantocellular reticular nucleus and inferior olive (Suppl. Figs. 10-
12). The inferior olive area also showed high vascular transduction (Suppl. Fig. 12I).  
The peripheral tissue transduction profiles showed differences among the three marmosets. 
While all three injected animals showed little muscle transduction (data not shown), liver 
transduction was robust in the animal treated with I.V. rAAVrh.10EGFP (Fig. 8A) but 
substantially reduced in the animal treated with I.V. rAAVrh.10EGFP-miRBS (Fig. 8C), thus 
suggesting that the incorporation of the endogenous miRNA-targeting sites can de-target rAAV 
expression in liver. Likewise, physically restricted CNS gene delivery by intrathecal injection of 
rAAVrh.10EGFP remarkably limited EGFP transduction in the liver (Fig. 8C) despite its robust 
transduction of motor neurons and dorsal root ganglion neurons throughout the spinal cord [27]. 
All three animals showed poor heart transduction (data not shown), thus we could not assess 
whether a particular treatment method reduced heart transduction. Interestingly, regardless of 
miRNA regulation or different routes of vector administration, the adrenal cortex expressed 
EGFP robustly in all 3 marmosets (Fig. 8B, D, F). 
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DISCUSSION 
It is well documented that intravascular delivered rAAVs are excellent vectors for CNS gene 
therapy in neonatal animals [4, 15, 31]. However, earlier studies in adult mice by I.V. injected 
rAAVs generated limited CNS transduction due to the advanced BBB development in adult 
animal models [17, 22, 32]. Here we demonstrate that several rAAVs are capable of crossing 
the BBB efficiently following I.V injection by using a semi-quantitative scoring system for a quick 
assessment of cell transduction efficiency. We opted for this method to evaluate rAAV 
transduction efficiency since it has been successfully applied and published previously [22, 33]. 
However, we recognize that the semi-quantitative scoring system has disadvantages in 
assessing absolute differences between serotypes. Thus, to differentiate the fine points among 
the rAAV serotypes, more extensive quantitative analyses will be needed. Another caveat of this 
study is the number of animals per group (n=3). Although, 3-4 animals per group are widely 
used to evaluate the transduction efficiency of rAAV [16, 17, 23, 25, 33], animal-to-animal 
variations even with inbred animals might influence the final results. To minimize this possibility, 
we injected male mice only. Despite the limitations of the method, the semi-quantitative 
characterization provides useful reference points for the future use of these AAV serotypes for 
I.V. delivery. 
Of all the rAAV serotypes tested, the most robust in crossing the BBB are the group 1 vectors 
consisted of rAAV8, rh.10 and 9 (Figs. 1-3; Suppl. Table 1). Although less robust than the 
group 1 vectors, the group 2 vectors, consisted of rAAV8, 7, rh.43 and rh.39, also show strong 
capability of transducing cells in broad CNS areas following I.V. injection. These results suggest 
that the group1 and group 2 vectors achieve similar results and expand the repertoire that may 
be used as alternative vectors to deliver therapeutic genes for treating CNS diseases via I.V. 
injection. It is worthwhile to point out that the grouping should not be interpreted as if there are 
absolute boundaries between the groups, but rather, it is used as a means to facilitate the 
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description of the large number of AAV serotypes tested and to provide a useful guide for 
selecting the most suitable vectors in future experimentation. 
Among the top vectors, a particular standout is the rAAVrh.8. With its global and robust 
transduction of the CNS cells, rAAVrh.8 consistently ranked first in broad CNS areas and in 
different cell populations (Fig. 3). A particularly attractive feature for rAAVrh.8 is its naturally 
lower peripheral tissue dissemination than other vectors, particularly in the liver (Fig. 6), which 
enhances the safety profile of systemic gene delivery to the CNS. These qualities suggest that 
rAAVrh.8 is a top candidate vector for treatment of the CNS diseases that afflict broad areas of 
the CNS. For example, the broad transduction of the forebrain areas is a property that can be 
applied to treat Alzheimer’s disease, which causes neurodegeneration in forebrain areas [34]. 
Similarly, the robust transduction throughout the spinal cord, brainstem and cortex are 
characteristics desirable for treatment of amyotrophic lateral sclerosis (ALS) and Canavan’s 
disease. ALS causes motor neuron degeneration in cortex, brainstem and spinal cord [35]. 
Canavan’s disease causes neurodegeneration throughout the CNS due to deficiency in 
aspartoacylase [4]. Of note, rAAV9 displays similar transduction qualities by I.V. injection in the 
spinal cord of adult mice, as reported previously [36], although it ranked slightly below the 
performance of rAAVrh.8 in side-by-side comparisons (Fig. 2 and 3). However, a direct 
comparison with previously published data is often complicated due to possible differences in 
vector production, dose and quantification methods [36]. 
 
The robust transduction of the CNS cells following I.V. injection is a surprising but useful 
character of some rAAV vectors. How these rAAVs cross the BBB remains elusive [32, 37, 38]. 
Nevertheless, our results suggest two possible routes for the rAAVs to enter and transduce the 
CNS. First, the rAAVs might cross the BBB by exploiting the fenestrated capillary vessels of 
circumventricular organs [39]. This is supported by the fact that we consistently observed strong 
EGFP expression in or near circumventricular organs such as the choroid plexus (Fig. 1; Suppl. 
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Fig. 4) in lateral (not shown), 3rd (Suppl. Fig. 4) and 4th (not shown) ventricles, organum 
vasculosum of the lamina terminalis (OVLT, not shown) and the sub-fornical organ (SFO, not 
shown). Upon close examination of the choroid plexus and its surrounding areas, we noticed 
EGFP-expressing ependymal cells (e.g. see ventricle below corpus callosum in the rAAVrh.43 
and rAAVrh.10 panels in Suppl. Fig. 2). Additionally, we also noticed the intense EGFP 
expression in neurons and glia near the 3rd ventricle (e.g. the area between the corpus callosum 
and the third ventricle in the AAVrh. 8 panel in Suppl. Fig. 2). The second possibility could be 
the direct transcytosis of rAAVs via endothelia [38], which represent the most inner layer of 
blood vessels. Perivascular astrocytes have been shown to regulate the tightness and 
exchange of molecules across the BBB [11, 40, 41]. Therefore, the presence of intensely 
stained blood vessels and their surrounding astrocytes suggests that rAAVs use this second 
route of entry into the CNS (Fig. 4 and Suppl. Figs. 2 and 3). Further studies will be needed to 
understand the transduction mechanism of rAAVs. 
 
A critical step in the clinical development of systemic gene delivery to the CNS by rAAV 
therapeutics is its translation from small (i.e. murine) to large animal models (i.e. NHP). The 
phylogenetic and physiological adjacency of nonhuman primates (i.e. marmoset) to humans 
supports NHP as an adequate model for evaluating gene transfer efficacy and safety. For 
systemic delivery, marmosets (Callithrix jacchus) are advantageous as an experimental animal 
model for their small body size and remarkably reduced vector needs. Marmosets have been 
extensively used for the investigation and treatment of CNS-related pathologies such as 
Parkinson’s and Huntington’s diseases [24, 42-44]. Previously, systemically delivered rAAV9 
has been evaluated in NHP animals for CNS targeting with promising results [16-18]. In our 
proof-of-concept study, we systemically delivered rAAVrh.10 for the first time to the CNS of the 
NHP marmosets and noticed some unique characteristics in the resulting transduction pattern. 
I.V. injection of rAAVrh.10 robustly transduced the motor neurons in the spinal motor column 
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and brainstem but scattered neurons and astrocytes in the forebrain and cerebellum (Fig. 7; 
Suppl. Figs. 6-11). These findings contrast with what was reported for intravascular delivered 
rAAV9 in cynomologus macaques, which transduced mostly astrocytes in the brain [15, 23, 45]. 
The causes for these differences are not clear but could be attributed to differences in the vector 
biology between rAAV9 and rAAVrh.10, animal species (i.e. cynomologus versus marmoset) 
and age, etc. In any case, the data generated from a single marmoset with known high animal-
to-animal variations in outbred NHP animals is a major caveat of our NHP study. More 
extensive studies will be required to confirm the vector biology of rAAVrh.10, and perhaps more 
importantly, to assess the performance of the rAAVrh.8 vector in marmosets or other NHP 
species. 
 
In this study, we also attempted translating the design of miRNA-regulated transgene 
expression from murine to a NHP model. Endogenous miRNA-mediated posttranscriptional 
regulation of transgene expression is an attractive method to detarget rAAV transduction from 
non-target tissues and cell types and will be desirable to prevent potential peripheral transgene 
toxicity as well as transgene directed immune response in peripheral tissue [29]. This strategy is 
effective in mice as we and others have demonstrated previously [26, 46-48]. Considering the 
conservation of miRNA sequences between human, marmoset and mouse, particularly the high 
homology of mir-122 and mir-1 (about 99%) [49], we tested this design in marmoset, which is 
the first application of this kind in rAAV gene transfer in primates. Indeed, our data 
demonstrated the effectiveness in detargeting of rAAVrh.10 expression from major peripheral 
tissues e.g. liver. It is rather interesting that rAAVrh.10 robustly transduced adrenal gland 
regardless of miRNA-detargeting and route of administration, which may hold promise for some 
clinical applications such Addison’s disease [50]. However, the CNS transduction of miRNA-
regulated vectors seemed to be underwhelming as compared to the vector without miRNA 
binding sites. Again, it is difficult to draw a firm conclusion from an experiment that includes only 
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one animal in each experimental group. Nevertheless, our findings suggest that combining the 
capability of I.V. rAAVrh.10 with miRNA-mediated tissue detargeting could be an effective 
means in tailoring rAAV and their tropism to reduce unwanted peripheral transgene toxicity. 
 
In summary, our study has revealed that many rAAVs are capable of crossing the BBB and 
transducing the CNS cells. Of these, the group 1 vectors, including rAAVrh.8, rAAVrh.10 and 
rAAV9 have demonstrated the strongest capacity for transducing CNS cells after the systemic 
I.V. injection. Importantly, rAAVrh.8 appears superior to its group 1 peers in its global CNS 
transduction and decreased peripheral tissue targeting, and thus, is the best rAAV for delivering 
CNS gene therapy via I.V. injection. Finally, the synergy of spinal motor neuron tropism of 
systemically delivered rAAVrh.10 and miRNA-silenced transgene expression in the peripheral 
tissues of primates may offer a promising treatment for a wide spectrum of degenerative motor 
neuron diseases. 
 
MATERIALS AND METHODS 
Vector cloning and production. The structure of the EGFP reporter vector genome was the 
same as previously described (Zhang et al., Mol. Ther. 2011). The miRNA-regulated EGFP 
construct was created by inserting 3 copies each of miR-1 and miR-122 target sites in tandem in 
the 3’ UTR of EGFP reporter gene as previously described (Xie et al., Mol. Ther. 2011). 
Production and quality control testing of rAAV vectors were the same as previously described 
(Zhang et al., Mol. Ther. 2011). Multiple batches of all different serotypes were prepared and 
injected. 
Animal injections. All animal procedures were approved by the Institutional Animal Care and 
Use Committees of University of Massachusetts Medical School (mouse study) and Harvard 
University Medical School (Marmoset study). For the mouse study, 10 week-old C57BL/6 mice 
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(n=3) were treated with rAAV vectors via tail vein injections at a dose of 4 x 10e12 GCs/mouse 
in 100 µl (2 x 10e14 GC/kg) and an average body weight of 20 gram. For the marmoset study, 
4-6 year-old marmoset monkeys were first screened for serologically neutralizing antibody 
against rAAVrh.10. One sero-negative animal each was selected for the intravenous injection of 
rAAVrh.10 EGFP or rAAVrh.10EGFP-3XMRBS via an intravenous catheter placed in the 
saphenous vein at a dose of 5x10e13 GCs/kg.   
Histological processing. Mice were anesthetized 21 days post-injection and transcardially 
perfused with 15 mL of cold PBS followed by 15 mL of fixation solution containing 4% 
paraformaldehyde (PFA) (v/v) in PBS. Brain and spinal cord were extracted and post fixed in 4% 
PFA overnight (n=3). Marmosets were euthanized at day 14 post-vector dosing and subjected 
to perfusion and fixation with 4% paraformaldehyde for histological analysis. The mouse and 
marmoset tissues were cryoprotected in 30% sucrose (w/v) in PBS, embedded in Tissue-Tek 
OCT compound (Sakura Finetek, Torrance, CA) and frozen in a dry ice/ethanol bath. Serial 40 
µm floating sections of the entire brain as well as 3 mm segments from cervical, thoracic and 
lumbar regions of the spinal cord were cut with a Cryostat (Thermo Microm HM 550).  
Immunohistochemistry. Free-floating sections of the Brain and spinal cord were incubated in 
blocking buffer containing 0.1% Triton-X100 (v/v) (Fisher, Pittsburg, PA) and 10% goat serum 
(v/v) (Invitrogen) for 1h at room temperature. The sections were then incubated at 4C overnight 
with primary antibodies diluted in blocking buffer. The following day tissue sections were 
washed twice in 0.05% Tween-20 (v/v) in PBS (PBST) and once with PBS, with each washing 
step lasting 10 min. Sections were subsequently incubated with appropriate secondary 
antibodies in blocking buffer for 1 h at room temperature. For fluorescent detection, sections 
were mounted with Vectashield with DAPI (Vector Laboratories, Burlingame, CA) and analyzed 
using an epifluorescent microscope (Nikon Eclipse Ti). For Avidin Biotin Complex-3,3'-
Diaminobenzidine (ABC-DAB) detection, sections were incubated in 0.1% peroxide/PBS and 
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
biotin/avidin blocking solution prior to primary antibody incubation to quench endogenous 
peroxidase and biotin activity. After incubation with a biotinylated secondary antibody, sections 
were washed and incubated in ABC reagent (PK-6200, VectorLabs) for 30 minutes at room 
temperature. After a quick wash in PBS, sections were developed with DAB solution (SK-4105, 
VectorLabs) for 60 seconds followed by 3 consecutive washes in PBS lasting 5 minutes each. 
Sections were subsequently dehydrated in a graded ethanol series of 50%, 70%, 95%, 100%. 
After 2 changes of Xylenes, sections were coverslipped with permount mounting media (Fisher) 
and left overnight to dry. The primary antibodies used in this study were as follows: rabbit anti-
GFP (Invitrogen), goat anti-ChAT and mouse anti-NeuN (both from Millipore, Billerica, MA), 
mouse anti-GFAP (Cell signaling, Danvers, MA), rabbit anti-CD31 (Abcam, Cambridge, MA), 
mouse anti-Calbindin D-28k (Sigma, St Louis, MO) and mouse anti-tyrosine hydroxylase 
monoclonal antibody (Millipore, Billerica, MA). 
Semi-quantitative analysis of EGFP positive cells transduced by rAAVs. We reviewed clinically 
relevant regions including cortex, corpus callosum, hippocampus, striatum, cerebellum, 
thalamus and medulla of the brain as well as cervical, thoracic and lumbar sections of the spinal 
cord (Figs. 1, 2 and 4; Suppl. Figs. 1, 2 and 3). To provide a semi-quantitative measure of the 
amount and type of cells that were transduced by rAAVs in the CNS, we used a previously 
described [22] scoring system that was originally developed by Cearley et al. [33]. Briefly, the 
number of (+) corresponds to the number of EGFP positive cells where (+) means very few 
positive cells, (++) some positive cells, (+++) many positive cells, (++++) large areas of positive 
cells and (+++++) saturated with positive cells. Regions with no EGFP expression is marked as 
(-). Mean scores were calculated by averaging plus signs for all brain and all spinal cord areas 
(n=3). The cell morphology of these sections was used to identify EGFP positive astrocytes, 
oligodendrocytes and neurons in multiple sections of any given region for each serotype. 
Sections of rAAVrh.8-transduced cells were stained for different cell markers to confirm the cell 
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identity (see Fig. 5). Statistical analysis was performed using one-way ANOVA test for 
comparison of semi-quantitative scores as well as biodistribution data. 
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FIGURE LEGENDS 
 
Figure 1. General transduction characteristics of 12 rAAVs in the adult mouse brain. 
rAAVEGFPs were injected into the tail vein of 10 week-old mice at 4x1012  genome copies (GCs) 
per mouse (n=3). Forty micrometer frozen sections of CNS tissues were obtained 21 days post 
injection and stained with antibody against EGFP. Staining was visualized with an Avidin-Biotin 
Complex / 3,3'-Diaminobenzidine substrate system. Shown are composite images of bregma 
-2.00mm brain sections of rAAV injected mice organized into four groups based on EGFP semi-
quantitative score and extend of distribution. Bar = 1000μm. 
 
Figure 2. General transduction characteristics of 12 rAAVs in the adult mouse spinal cord. 
rAAVEGFPs were injected into the tail vein of 10 week-old mice at 4x1012  genome copies (GCs) 
per mouse (further description see Fig. 1, n=3). Shown are composite images of CSC (cervical 
spinal cord), TSC (thoracic spinal cord) and LSC (lumbar spinal cord) sections of rAAV injected 
mice organized into four groups based on EGFP semi-quantitative score and extend of 
distribution. Bar = 250μm. 
 
Figure 3. Quantification of transduced cell types in the CNS of adult mice.  
Semi-quantitative scores of neuronal and glia cell types transduced by different rAAVEGFPs. 
EGFP positive CNS cell types are microscopically scored and the means of rAAV transduced 
astrocytes, neurons and oligodendrocytes in the brains and spinal cords are shown (n=3). ** 
p<0.0033, *** p<0.001, ****p<0.0001, ns = non-significant. 
 
Figure 4. Transduction profile of various neuronal populations by rAAVrh.8.  
rAAVrh.8 vectors were injected into the tail vein of 10-week-old mice at 4x1012  genome copies 
per mouse. Staining for EGFP was carried out as described in Fig. 1 legend. Shown are the 
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
compilation of high magnification images of CNS cell transduction and their corresponding 
locations in a low magnification view at bregma -2.00mm (A-I) as well as some other clinical 
relevant brain regions (i.e. OB=olfactory bulb, SN=substantia nigra and LSN=lateral septal 
nucleus and cerebellum) that were not present in the lower magnification view of the selected 
brain section. DG=dentate gyrus, CC=corpus callosum, CA2=CA2 region of hippocampus. Bars 
in A, C, H = 10µm. Bars in D, F, I = 15µm and bars in B, E, G, J, K, L = 20µm 
 
Figure 5. Identifying CNS cell types transduced in the adult mice that received I.V. 
injection of rAAVrh.8EGFP. Sections were stained with antibodies against EGFP, NeuN 
(neurons), GFAP (astrocytes), APC (oligodendrocytes), Iba1 (microglia), CD31 (blood vessels). 
Objective 60x. Bar = 20um 
 
Figure 6. Biodistribution profiles in mice. (A) Biodistribution profiles of rAAVEGFPs in the 
adult mice after I.V. injections. Persisted rAAVEGFP vector genomes in 8 different tissues of 
rAAV treated mice were quantified by qPCR using primers/probe set targeting poly A region of 
the vector genome (n=3). (B). Ratios of vector genomes detected in the brains to those in the 
liver, heart, lung and pancreas tissues respectively (n=3). **** p < 0.0001, ns = non significant 
 
Figure 7.  Robust EGFP transduction in the spinal cord and midbrain of an adult 
marmoset received I.V. injected rAAVrh.10EGFP. A 4 year-old male marmoset was I.V. 
injected with rAAVrh.10CBEGFP at a dose of 5x10e13 GCs/kg and necropsied 2 weeks later. 
The CNS tissues were isolated, fixed, sectioned, and stained for EGFP as described in Methods 
and Fig 1 legend. All sections were counterstained with Haematoxylin. (A, C, E) Low 
magnification images of cervical, thoracic and lumbar spinal cord. (B, D, F) High magnification 
of the boxed areas showing the transduced motor neurons in A, C and E, respectively. (G, H) 
Low magnification images of ventral midbrain. (I) High magnification of the boxed areas in G 
ACCEPTED ARTICLE PREVIEW 
© 2014 The American Society of Gene & Cell Therapy. All rights reserved 
and H showing well transduced motor neurons in the oculomotor nucleus (3N). Bars in A, C, E, 
G, H = 200μm. Bars in B, D, F, I = 100μm.  
 
Figure.8. EGFP transduction of peripheral tissues in adult marmosets treated with I.V. or 
I.T. injected rAAVrh.10EGFP or EGFP3XMRBS vector. Male adult marmosets were I.V. 
injected with rAAVrh.10CBEGFP or rAAVrh.10CBEGFP-(miR-1BS)3-(miR-122BS)3 at a dose of 
5x10e13 GCs/kg or I.T. injected with rAAVrh.10CBEGFP at a dose of 2.7x10e12 GCs/kg. Eight 
micrometer sections of peripheral tissues were counter stained with DAPI fluorescence and 
microscopically evaluated for native EGFP expression. Presented are the fluorescent images of 
native EGFP expression (overview 100X, insets 400X objective) of liver (a, c, e) and adrenal 
gland (b, d, f) tissues of adult male marmosets received rAAVrh.10EGFP by I.V. (a, b) or I.T. (e, 
f) injection or rAAVrh.10EGFP3XmiRBS by I.V. injection (c, d). Bars in a-i = 50 μm. Bars in 
insets 10 μm. 
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Supplementary Figure 1. Motor neuron transduction patterns of different rAAVEGFPs in 
the lumbar spinal cords of adult mice. rAAVs were injected into the tail vein of 21 day-old 
mice at 4x1012  genome copies per mouse (n=3). Staining and visualization was performed as 
described in legend of Fig. 1. The microscopic images of lumbar spinal cord sections are shown 
for each rAAV. Black arrows indicate motor neurons expressing EGFP. Black boxes are 
representative high magnification views of motor neurons expressing EGFP. Bar = 200μm. 
 
Supplementary Figure 2. Regional transduction patterns of rAAVs in the adult mouse 
brains. rAAVEGFPs were injected into the tail vein of 10 week-old mice at 4x1012  genome 
copies per mouse. Forty micrometer frozen sections were obtained 21 days post injection and 
stained and visualized for EGFP as described in Fig. 1 legend. Cortex, corpus callosum, 
hippocampus, striatum, cerebellum, thalamus and medulla are shown for each rAAV-injected 
mouse. 10x objective. Bar = 100μm. 
 
Supplementary Figure 3. Transduction profiles of various neuronal populations by 
rAAVrh.10 and 9. rAAVrh.10 and 9 vectors were injected into the tail vein of 10-week-old mice 
at 4x1012  genome copies per mouse (n=3). Staining for EGFP was carried out as described in 
Fig. 1 legend. Shown are the compilation of high magnification images of CNS cell transduction 
and their corresponding locations in a low magnification view at bregma -2.00mm (A-I) as well 
as some other clinical relevant brain regions (i.e. cerebellum, substantia nigra and lateral septal 
nucleus) that were not present in the lower magnification view of the selected brain section (J-L). 
For localization of anatomical regions see Fig. 4. Bars in A, C, H = 10µm. Bars in D, F, I = 15µm 
and bars in B, E, G, J, K, L = 20µm 
 
Supplementary Figure 4. Choroid plexus transduction pattern of different I.V. delivered 
rAAV serotypes in mouse.  Shown are representative EGFP staining signals in coronal 
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sections of the corpus callosum and third ventricle demonstrating the transduction of the choroid 
plexus by different rAAV serotypes. Bar = 200µm 
 
Supplementary Figure 5. Identifying neuronal populations transduced in the adult mice 
that received I.V. injection of rAAVrh.8EGFP. Sections were stained with antibodies against 
EGFP, Calbindin (Purkinje cells), ChAT (motor neurons), Drapp-32 (medial spiny neurons) and 
tyrosine hydroxylase (TH; dopaminergic neurons). Objective 60x. Bar = 20um. 
 
Supplementary Figure 6. EGFP transduction of different regions in the spinal cords of an 
adult marmoset received I.V. injected rAAVrh.10EGFP. High magnification images of the 
posterior horn and intermediate zone regions of spinal cord sections presented in Fig. 7. (A, B) 
Cervical spinal cord, (C, D) thoracic spinal cord, and (E, F) lumbar spinal cord. (A, C, E): 
posterior horn and (B, D, F): intermediate zone. Bars=50μm.  
 
Supplementary Figure 7. EGFP transduction of different regions in the medulla oblongata 
of an adult marmoset received I.V. injected rAAVrh.10EGFP. Low magnification images  of 
(A) dorsolateral, (B) dorsal median and (C) ventrolateral medulla oblongata.  The red boxes in A, 
B and C were enlarged in D, E and F, respectively. The blue boxes in A, B and C were enlarged 
in G, H and I, respectively. VeN: vestibular nucleus; 12N: hypoglossal nucleus; py: pyramidal 
tract; IO: inferior olive; icp: inferior cerebellar peduncle; Sp5: spinal trigeminal nucleus; sp5: 
spinal trigeminal tract; LRt: lateral reticular nucleus. Bars in A-C = 200μm, Bars in D-I = 100μm.  
 
Supplementary Figure 8. EGFP transduction of different regions in the ventral midbrain 
of an adult marmoset received I.V. injected rAAVrh.10EGFP. High magnification images  of 
selected regions in ventral midbrain shown in Fig.7 G and H. (A, B):  Red nucleus (RN). (C) 
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Ventrolateral midbrain region with substantia nigra (SN) marked with a blue box. (D) An 
enlarged view of SN region marked with a blue box in (C). Bars in A, B, D = 100μm. Bar in C 
=200μm. 
 
Supplementary Figure 9. Sparse neuronal EGFP transduction of some brain regions in an 
adult marmoset treated with I.V. injected rAAVrh.10EGFP. (A, C, E) are low magnification 
images of cerebellum, hippocampus and cortex, respectively. (B, D, F) are enlarged views of 
the red boxes in A, C and E, respectively. Bars in A, C, E = 100μm, Bars in B, D, F = 50μm.  
 
Supplementary Figure 10. Sparse EGFP transduction of the CNS tissues in an adult 
marmoset treated with I.V. injected rAAVrh.10EGFP3XmiRBS. (A, B, C) show low 
magnification images of EGFP transduction in the thoracic and lumbar spinal cord, and midbrain 
regions, respectively  (D, E, F) are high magnification views of the red boxes in A, B and C, 
respectively. (G, H, I) are high magnification images of the blue boxes in A, B and C, 
respectively. 3N: oculomotor nucleus. Bars in A-C = 200μm; Bars in D-I = 50μm.  
 
Supplementary Figure 11. EGFP transduction of several brain regions in an adult 
marmoset treated with I.V. injected rAAVrh.10EGFP3XmiRBS.  (A, C, E) are low 
magnification images of cerebellum, hippocampus and cortex regions, respectively. (B, D, F) 
are enlarged views of the red boxes in A, C and E, respectively. Bars in A, C, E = 200μm. Bars 
in B, D, F = 50μm. 
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Supplementary Figure 12. EGFP transduction of the CNS in adult marmosets treated with 
I.V. injected EGFP3XMRBS vector. Male adult marmosets were I.V. injected with 
rAAVrh.10CBEGFP-(miR-1BS)3-(miR-122BS)3 at a dose of 5x10e13 GCs/kg. Low magnification 
images (A) cervical spinal cord, (B) dorsolateral and (C) ventrolateral medulla oblongata. (D, E, 
F) High magnification images of the red boxed areas in A, B and C, respectively. (G, H, I) High 
magnification images of the blue boxed areas in A, B and C, respectively. 12N: hypoglossal 
nucleus; 10N: nucleus of vagus. Gi: gigantocellular reticular nucleus; IO: inferior olive.  Bars in 
a-c = 200μm. Bars in d-I = 50μm.  
 
Supplementary Table 1. The 12 different rAAV serotypes are listed according to the semi-
quantitative analysis. 
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Figure 3 
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Figure 4 
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Figure 6 
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Figure 7 
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